Urolithin A and mitophagy in aging muscle: what the 2024 trials actually showed.

What urolithin A is, and where it comes from

Urolithin A (UA) is a gut-derived metabolite — specifically, a postbiotic. It is not present in food directly. Instead, it is produced by the gut microbiome when ellagitannins and ellagic acid from certain foods are metabolized by specific bacterial strains. The dietary precursor foods include pomegranate (the richest source), walnuts, raspberries, strawberries, and some oak-aged wines and teas. The ellagitannins in those foods get hydrolyzed to ellagic acid in the gut, and certain bacteria — primarily Gordonibacter urolithinfaciens, Gordonibacter pamelaeae, and strains associated with Akkermansia — convert ellagic acid stepwise into urolithins including urolithin A [1].

The key point, and the one the supplement marketing routinely buries: eating pomegranate does not reliably produce urolithin A in most people. The conversion depends entirely on whether your specific gut microbiome contains the right bacteria at sufficient abundance. Most people's don't.

Timeline Nutrition (the commercial arm of Swiss biotech Amazentis) has developed Mitopure — a purified, standardized dose of urolithin A synthesized outside the gut — to sidestep the conversion problem entirely. Mitopure delivers 500–1000 mg of urolithin A directly, with measurable plasma levels achieved regardless of gut microbiome composition [2].

The conversion problem: most people don't make it from food

The gut microbiome variability around urolithin production is one of the more consistent findings in the literature, and one the supplement industry almost never discusses honestly. Research on urolithin metabotypes has identified three distinct producer phenotypes:

• Metabotype A (UM-A): Produces urolithin A efficiently. These individuals respond to dietary ellagitannin consumption with measurable circulating urolithin A levels.
• Metabotype B (UM-B): Produces a mix of urolithins including urolithin B and isourolithin A, but lower UA specifically.
• Metabotype 0 (UM-0): Non-producers. No meaningful urolithin conversion occurs regardless of dietary intake. In some studied cohorts, the non-producer phenotype represents 30–40% of the adult population [1].

A 2021 study published in the European Journal of Clinical Nutrition tested this directly: only about 40% of participants showed significant urolithin A conversion after a pomegranate dietary challenge. A separate analysis noted that across cohorts, only around 12% of participants had circulating UA at measurable baseline levels without dietary challenge at all [2].

The implication is straightforward. If you are in the 30–40% non-producer phenotype, no amount of pomegranate juice changes your urolithin A status. You are not converting. Direct supplementation with Mitopure bypasses this entirely, which is the actual clinical case for the supplement in healthy adults — not the vague "pomegranate in a pill" framing that most marketing uses.

In 30–40% of adults, the gut simply cannot convert dietary ellagitannins into urolithin A. The supplement solves a real biological problem — the marketing just never explains what that problem is.

The mitophagy signal: what the mechanism studies show

Mitophagy is the selective autophagy of damaged or dysfunctional mitochondria — a cellular housekeeping process by which the cell clears out defective mitochondria and replaces them with new, functional ones. The signal that urolithin A activates mitophagy was initially shown in C. elegans and mammalian cell models, and then confirmed in human skeletal muscle cells in vitro. The mechanism involves upregulation of autophagy-related proteins and the PINK1/Parkin pathway, which tags damaged mitochondria for lysosomal degradation [3].

The 2019 Nature Metabolism paper from Andreux and colleagues at Amazentis established the first human evidence that oral urolithin A (at 500 mg and 1000 mg doses) produced a statistically significant upregulation of mitophagy-associated gene expression in skeletal muscle biopsies in healthy sedentary older adults compared to placebo [4]. Acylcarnitine levels — indirect markers of mitochondrial efficiency — also dropped significantly, suggesting improved mitochondrial function.

This was real, peer-reviewed, published science. It was also, importantly, a mechanistic study, not a functional outcomes trial. Gene expression changes and acylcarnitine levels tell us the cellular machinery is responding. They do not, by themselves, tell us whether people can lift more weight or walk further. That required the subsequent functional trials.

The JAMA Network Open trial: older adults, real endpoints

The most rigorous functional trial published to date appeared in JAMA Network Open in 2022 [5]. The study enrolled older adults (average age ~65) in a randomized, placebo-controlled design. Participants received either 1000 mg of urolithin A (Mitopure) daily or placebo for 4 months. Primary and secondary endpoints included muscle endurance (hand grip, walking distance), aerobic capacity (VO2 peak), and mitochondrial biomarkers.

The results were real but modest — and the supplement industry has selectively reported them. The honest summary:

• VO2 peak: Significant improvement versus placebo. This is the cleanest functional finding in the trial — aerobic capacity improved measurably.
• 6-minute walk test: Clinically meaningful improvement observed in the UA group compared to placebo.
• Peak power output: The primary endpoint. Did not reach statistical significance. This is the number the marketing omits.
• Mitochondrial biomarkers: Acylcarnitines and C-reactive protein significantly lower in the UA group, replicating the 2019 mechanistic findings.

The correct read: urolithin A improved aerobic endurance markers and mitochondrial health indicators in sedentary older adults. It did not demonstrate a statistically significant effect on the primary power output endpoint. The effect size on secondary functional measures was real but would not show up in someone already training consistently.

The Cell Reports Medicine trial: middle-aged adults, strength data

The 2022 Cell Reports Medicine trial extended the population down in age — enrolling middle-aged adults (40–65) rather than older adults, and adding a higher dose arm (2000 mg) alongside the standard 1000 mg and placebo [6]. This trial also ran for 4 months and was randomized and placebo-controlled.

The headline finding that made it into supplement marketing: leg muscle strength improved by approximately 12% in the UA groups versus placebo. This is real, and it is meaningful. But the context matters:

• Participants were sedentary at baseline. A ~12% strength improvement in sedentary middle-aged adults from supplementation alone represents a real physiological signal — but anyone who begins even a modest resistance training program would expect to see larger gains in the same time window.
• Exercise performance markers (handgrip, 6-min walk, aerobic endurance) also improved, consistent with the JAMA trial.
• There was no statistically significant dose-response advantage at 2000 mg versus 1000 mg, which somewhat limits the mechanistic interpretation of dose-titration.

The mitochondrial health biomarkers again improved significantly — plasma acylcarnitines down, mitochondrial gene expression up in skeletal muscle biopsies. The cellular machinery is responding. The question of whether that response translates to meaningful functional gains in already-active adults remains genuinely open.

2024 and 2025 updates: athlete trials and immune data

A 2024 trial published in the Journal of the International Society of Sports Nutrition examined urolithin A in male athletes undergoing resistance training over 8 weeks [7]. This is the more practically relevant population for most buyers of Mitopure, and the results were more modest. Muscle endurance and recovery markers improved over placebo, but strength gains (1RM measures) did not separate significantly from placebo in athletes who were already training consistently.

A separate 2024 nutraingredients-reported trial (as of publication, in the preprint phase) examined Mitopure in young men, again showing endurance and recovery improvements but similar null results on primary strength outcomes in trained individuals [8].

The pattern across trials is now fairly consistent: urolithin A produces reliable mitochondrial health biomarker improvements and meaningful aerobic endurance gains, particularly in sedentary or moderately active older adults. The effect attenuates considerably in people who are already exercising regularly. This is not a failure of the compound — it is what you would expect from a mitochondrial quality-control activator: it has more room to operate when mitochondrial housekeeping is already poor (sedentary aging) than when it is being maintained through regular metabolic demand (consistent training).

In 2025, Timeline also published data showing urolithin A's effects on immune resilience and cardiovascular markers, which point to a broader application than purely muscular — but these data are newer, from smaller trials, and require independent replication before they meaningfully change the cost-benefit calculation for most buyers.

Who actually needs the supplement, and who doesn't

Based on the trial data as it stands, the clearest candidate for urolithin A supplementation is a sedentary or lightly active adult over 50 who wants to preserve muscle quality and aerobic capacity as they age, is in a non-converter or low-converter metabotype (or simply doesn't eat enough ellagitannin-rich foods consistently), and is not currently doing structured resistance training.

The picture changes when you layer in regular training. If someone is already doing 3–4 sessions of resistance training per week, the mitochondrial stimulus from exercise is substantial — it activates many of the same PINK1/Parkin pathways urolithin A targets. The incremental benefit of adding $50+/month on top of that training stimulus is unclear. The trials have not been run in this specific population at sufficient scale to give a definitive answer.

The price reality: $50+/month versus pomegranate and resistance training

Mitopure retails at $50–70 per month for the 500 mg gummy or powder form (1000 mg requires two servings). This is meaningful money over a year. The honest comparison is not Mitopure versus pomegranate juice — it is Mitopure versus a structured resistance training program.

A 2024 meta-analysis of resistance training in middle-aged and older adults (unrelated to urolithin A) reported leg strength gains of 15–25% over 4 months of consistent training in previously sedentary participants — a larger effect than the 12% seen in the Cell Reports Medicine UA trial, at the cost of gym membership or bodyweight programming, not $50/month in supplements. Resistance training also directly activates mitophagy via exercise-induced metabolic stress [9].

This is not an argument against urolithin A. It is an argument for framing it correctly. Mitopure is a mitochondrial support compound with real trial data behind it, genuine utility for non-converter metabotypes and sedentary older adults, and a price point that deserves honest scrutiny. It is not a substitute for exercise. It is not going to produce dramatic body composition changes in trained individuals. The trials don't support that claim, and a careful read of the data makes that clear.

For sedentary adults over 50 who are not yet training, the calculus is different: urolithin A at 1000 mg/day may be a meaningful bridge intervention to preserve mitochondrial quality while they build toward a consistent exercise habit — and for non-converter metabotypes, the dietary alternative simply doesn't exist. That is the honest case for the supplement. It's a real case. It's just narrower than the marketing suggests.